pubmed.ncbi.nlm.nih.gov

Ventricular assist devices: is destination therapy a viable alternative in the non-transplant candidate? - PubMed

Review

Ventricular assist devices: is destination therapy a viable alternative in the non-transplant candidate?

Tara Hrobowski et al. Curr Heart Fail Rep. 2013 Mar.

Abstract

The topic of this article, stated a more familiar way, is whether left ventricular assist devices (LVADs) are ready for 'Primetime' as a therapeutic option in and of themselves. In order to provide an update and insight on this question, we briefly review from where the field has come, and in more detail describe its current state and where we are heading. We believe the short answer to this question is 'Yes', but like many things, a short answer is not adequate. Here we attempt to deliver a more comprehensive answer, providing some historical context, outlining the great achievements that have been made, as well as the many challenges that still remain before LVADs become a truly mainstream therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1

Survival curves for REMATCH (9) and HeartMate II Destination (19) trials. From N Engl J Med, Fang JC, “Rise of the machines--left ventricular assist devices as permanent therapy for advanced heart failure,” Volume 361, Pages 2282-5. Copyright ©2009 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

Similar articles

Cited by

References

    1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics--2012 update: a report from the american heart association. Circulation. 2012;125:e2–e220. - PMC - PubMed
    1. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report--2011. J Heart Lung Transplant. 2011;30:1078–1094. - PubMed
    1. Hogness JR, VanAntwerp M Institute of Medicine (U.S.). Committee to Evaluate the Artificial Heart Program of the National Heart Lung and Blood Institute; National Heart Lung and Blood Institute. The artificial heart : prototypes, policies, and patients. Washington, D.C: National Academy Press; 1991. - PubMed
    1. Levitt JA. Thermo Cardiosystems, Inc. Premarket Approval of the HeartMateRegister IP LVAS. In: Services HaH, editor. Federal Register. 1996. pp. 51712–51713.
    1. Oz MC, Goldstein DJ, Pepino P, et al. Screening scale predicts patients successfully receiving long-term implantable left ventricular assist devices. Circulation. 1995;92:II169–II173. - PubMed

Publication types

MeSH terms